-+ 0.00%
-+ 0.00%
-+ 0.00%

Alterity says FDA backs single Phase 3 trial path to potential ATH434 approval in multiple system atrophy

PUBT·07/07/2026 11:05:47
Listen to the news
Alterity says FDA backs single Phase 3 trial path to potential ATH434 approval in multiple system atrophy
  • Alterity Therapeutics received FDA End-of-Phase 2 minutes confirming a registrational pathway for ATH434 in multiple system atrophy.
  • FDA indicated one pivotal Phase 3 trial, supported by confirmatory evidence, could support approval and a potential NDA filing.
  • Phase 3 planned to enroll about 200 patients for 12 months, testing ATH434 50 mg twice daily versus placebo.
  • Trial start remains targeted by year-end 2026; Phase 2 ATH434-201 data expected to serve as confirmatory evidence.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070705PRIMZONEFULLFEED9757895) on July 07, 2026, and is solely responsible for the information contained therein.